SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-24-078771
Filing Date
2024-06-28
Accepted
2024-06-28 07:30:04
Documents
2
Period of Report
2024-06-26

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1597
2 EX-24.NIAPOA verv-ex24_niapoa.htm EX-24.NIAPOA 11230
  Complete submission text file 0000950170-24-078771.txt   14288
Mailing Address C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210
Business Address
Tatsis Ourania (Reporting) CIK: 0001789815 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40489 | Film No.: 241081366

Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Issuer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)